Neuroprotective effects of various doses of topiramate against methylphenidate induced oxidative stress and inflammation in rat isolated hippocampus

Clinical and Experimental Pharmacology and Physiology

Volumn 43, Issue 3, 2016, Pages 360-371

  Motaghinejad, Majid ^a   Motevalian, Manijeh ^a   Shabab, Behnaz ^b  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b IranNajo Pharmaceutical Co   (Iran)

Author keywords

BDNF; Inflammation; Methylphenidate; Oxidative stress; Topiramate

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; INTERLEUKIN 1BETA; METHYLPHENIDATE; NEUROPROTECTIVE AGENT; SUPEROXIDE DISMUTASE; TOPIRAMATE; TUMOR NECROSIS FACTOR ALPHA; FRUCTOSE; GLUTATHIONE DISULFIDE; TUMOR NECROSIS FACTOR;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; CELL LOSS; CONTROLLED STUDY; DENTATE GYRUS; GENE EXPRESSION; HIPPOCAMPUS; INFLAMMATION; LIPID PEROXIDATION; MALE; MITOCHONDRION; MOTOR ACTIVITY; NEUROPROTECTION; NONHUMAN; OPEN FIELD TEST; OXIDATIVE STRESS; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM;

ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FRUCTOSE; GENE EXPRESSION REGULATION; GLUTATHIONE; GLUTATHIONE DISULFIDE; GLUTATHIONE REDUCTASE; HIPPOCAMPUS; INTERLEUKIN-1BETA; LIPID PEROXIDATION; MALE; METHYLPHENIDATE; MITOCHONDRIA; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; RATS; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84959349492     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12538     Document Type: Article

References (58)

1. Challman TD, Lipsky JJ. Methylphenidate: its pharmacology and uses. Mayo Clin. Proc. 2000; 75: 711-21.
2. Patrick KS, Markowitz JS. Pharmacology of methylphenidate, amphetamine enantiomers and pemoline in attention-deficit hyperactivity disorder. Human Psychopharmacol. Clin. Exper. 1997; 12: 527-46.
3. Tagaya H. Methylphenidate: pharmacology, indication and potential of abuse. Nihon rinsho. 2010; 68: 1550-5.
4. Huss M, Lehmkuhl U. Methylphenidate and substance abuse: a review of pharmacology, animal, and clinical studies. J. Atten. Disord. 2001; 6: S65-71.
5. Klein-Schwartz W. Abuse and toxicity of methylphenidate. Curr. Opin. Pediatr. 2002; 14: 219-23.
6. Babcock Q, Byrne T. Student perceptions of methylphenidate abuse at a public liberal arts college. J. Am. Coll. Health 2000; 49: 143-5.
7. Williams RJ, Goodale LA, Shay-Fiddler MA, Gloster SP, Chang SY. Methylphenidate and dextroamphetamine abuse in substance-abusing adolescents. Am. J. Addict. 2004; 13: 381-9.
8. Barrett SP, Pihl RO. Oral methylphenidate-alcohol co-abuse. J. Clin. Psychopharmacol. 2002; 22: 633-4.
9. Réus GZ, Scaini G, Jeremias GC et al. Brain apoptosis signaling pathways are regulated by methylphenidate treatment in young and adult rats. Brain Res. 2014; 1583: 269-76.
10. Zare S, Farrokhi F. The effect of oral administration of methylphenidate on hippocampal tissue in adult male rats. Neurosurg. Quart. 2014; 4: 33-39.
11. Martins MR, Reinke A, Petronilho FC, Gomes KM, Dal-Pizzol F, Quevedo J. Methylphenidate treatment induces oxidative stress in young rat brain. Brain Res. 2006; 1078: 189-97.
12. Garnett WR. Clinical pharmacology of topiramate: a review. Epilepsia 2000; 41(Suppl. 1): 61-65.
13. Arnone D. Review of the use of topiramate for treatment of psychiatric disorders. Ann. Gen. Psychiatry. 2005; 4: 1-14.
14. Lee S-R, Kim S-P, Kim J-E. Protective effect of topiramate against hippocampal neuronal damage after global ischemia in the gerbils. Neurosci. Lett. 2000; 281: 183-6.
15. Kudin AP, Debska-Vielhaber G, Vielhaber S, Elger CE, Kunz WS. The mechanism of neuroprotection by topiramate in an animal model of epilepsy. Epilepsia 2004; 45: 1478-87.
16. Kutluhan S, Naziroğlu M, Çelik Ö, Yilmaz M. Effects of selenium and topiramate on lipid peroxidation and antioxidant vitamin levels in blood of pentylentetrazol-induced epileptic rats. Biol. Trace Elem. Res. 2009; 129: 181-9.
17. Armağan A, Kutluhan S, Yilmaz M et al. Topiramate and vitamin E modulate antioxidant enzyme activities, nitric oxide and lipid peroxidation levels in pentylenetetrazol-induced nephrotoxicity in rats. Basic Clin. Pharmacol. Toxicol. 2008; 103: 166-70.
18. Dudley JT, Sirota M, Shenoy M et al. Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci. Transl. Med. 2011; 3: 76-96.
19. Vajda FJE. Neuroprotection and neurodegenerative disease. J. Clin. Neurosci. 2002; 9: 4-8.
20. Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 2000; 41: 3-9.
21. 2+ influx and oxidative stress in neuronal PC12 cells. Neurochem. Res. 2013; 38: 90-97.
22. Muriach M, López-Pedrajas R, Barcia JM, Sanchez-Villarejo MV, Almansa I, Romero FJ. Cocaine causes memory and learning impairments in rats: involvement of nuclear factor kappa B and oxidative stress, and prevention by topiramate. J. Neurochem. 2010; 114: 675-84.
23. Davids E, Zhang K, Tarazi FI, Baldessarini RJ. Stereoselective effects of methylphenidate on motor hyperactivity in juvenile rats induced by neonatal 6-hydroxydopamine lesioning. Psychopharmacology (Berlin) 2002; 160: 92-98.
24. Vendruscolo LF, Izídio GS, Takahashi RN, Ramos A. Chronic methylphenidate treatment during adolescence increases anxiety-related behaviors and ethanol drinking in adult spontaneously hypertensive rats. Behav. Pharmacol. 2008; 19: 21-27.
25. Khan S, Liberzon I. Topiramate attenuates exaggerated acoustic startle in an animal model of PTSD. Psychopharmacology (Berlin) 2004; 172: 225-9.
26. Molina-Hernández M, Téllez-Alcántara NP, Olivera-Lopez JI, Jaramillo MT. Antidepressant-like or anxiolytic-like actions of topiramate alone or co-administered with intra-lateral septal infusions of neuropeptide Y in male Wistar rats. Peptides 2010; 31: 1184-9.
27. Mula M, Pini S, Cassano GB. The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. J. Clin. Psychopharmacol. 2007; 27: 263-72.
28. Cagetti E, Baicy KJ, Olsen RW. Topiramate attenuates withdrawal signs after chronic intermittent ethanol in rats. NeuroReport 2004; 15: 207-10.
29. Lau JW, Senok S, Stadlin A. Methamphetamine-induced oxidative stress in cultured mouse astrocytes. Ann. N. Y. Acad. Sci. 2000; 914: 146-56.
30. Fagundes AO, Rezin GT, Zanette F et al. Chronic administration of methylphenidate activates mitochondrial respiratory chain in brain of young rats. Int. J. Dev. Neurosci. 2007; 25: 47-51.
31. Gibbs JE, Walker MC, Cock HR. Levetiracetam: antiepileptic properties and protective effects on mitochondrial dysfunction in experimental status epilepticus. Epilepsia 2006; 47: 469-78.
32. Agarwal NB, Agarwal NK, Mediratta PK, Sharma KK. Effect of lamotrigine, oxcarbazepine and topiramate on cognitive functions and oxidative stress in PTZ-kindled mice. Seizure 2011; 20: 257-62.
33. Price TO, Eranki V, Banks WA, Ercal N, Shah GN. Topiramate treatment protects blood-brain barrier pericytes from hyperglycemia-induced oxidative damage in diabetic mice. Endocrinology 2011; 153: 362-72.
34. Frey BN, Valvassori SS, Gomes KM et al. Increased oxidative stress in submitochondrial particles after chronic amphetamine exposure. Brain Res. 2006; 1097: 224-9.
35. Frey BN, Martins MR, Petronilho FC, Dal-Pizzol F, Quevedo J, Kapczinski F. Increased oxidative stress after repeated amphetamine exposure: possible relevance as a model of mania. Bipolar Disord. 2006; 8: 275-80.
36. Motaghinejad M, Karimian SM, Motaghinejad O, Shabab B, Asadighaleni M, Fatima S. The effect of various morphine weaning regimens on the sequelae of opioid tolerance involving physical dependency, anxiety and hippocampus cell neurodegeneration in rats. Fundam. Clin. Pharmacol. 2015; 29: 299-309.
37. Yürekli VA, Naziroğlu M. Selenium and topiramate attenuates blood oxidative toxicity in patients with epilepsy: a clinical pilot study. Biol. Trace Elem. Res. 2013; 152: 180-6.
38. Yano M, Steiner H. Methylphenidate and cocaine: the same effects on gene regulation? Trends Pharmacol. Sci. 2007; 28: 588-96.
39. Andreazza AC, Frey BN, Valvassori SS et al. DNA damage in rats after treatment with methylphenidate. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007; 31: 1282-8.
40. Naziroğlu M, Kutluhan S, Uğuz AC, Çelik Ö, Bal R, Butterworth PJ. Topiramate and vitamin E modulate the electroencephalographic records, brain microsomal and blood antioxidant redox system in pentylentetrazol-induced seizure of rats. J. Membr. Biol. 2009; 229: 131-40.
41. Cardenas-Rodriguez N, Coballase-Urrutia E, Huerta-Gertrudis B et al. Antioxidant activity of topiramate: an antiepileptic agent. Neurol. Sci. 2013; 34: 741-7.
42. Gomes KM, Petronilho FC, Mantovani M et al. Antioxidant enzyme activities following acute or chronic methylphenidate treatment in young rats. Neurochem. Res. 2008; 33: 1024-7.
43. Shanthakumar J, Tamilselvan T, Arunagiri P, Rajeshwaran K, Balamurugan E. Role of caffeine intake in lithium treated methylphenidate induced oxidative stress in an animal model of mania. Asian J. Pharm. Res. 2013; 3: 166-71.
44. Kuczenski R, Segal DS. Locomotor effects of acute and repeated threshold doses of amphetamine and methylphenidate: relative roles of dopamine and norepinephrine. J. Pharmacol. Exp. Ther. 2001; 296: 876-83.
45. Yamamoto BK, Raudensky J. The role of oxidative stress, metabolic compromise, and inflammation in neuronal injury produced by amphetamine-related drugs of abuse. J. Neuroimmune Pharmacol. 2008; 3: 203-17.
46. Sadasivan S, Pond BB, Pani AK, Qu C, Jiao Y, Smeyne RJ. Methylphenidate exposure induces dopamine neuron loss and activation of microglia in the basal ganglia of mice. PLoS ONE 2012; 7: e33693.
47. Lewis JJ, Iezzoni JC, Berg CL. Methylphenidate-induced autoimmune hepatitis. Dig. Dis. Sci. 2007; 52: 594-7.
48. Koçer A, Memişoğullari R, Domaç FM et al. IL-6 levels in migraine patients receiving topiramate. Pain Pract. 2009; 9: 375-9.
49. Scherer EB, da Cunha MJ, Matté C, Schmitz F, Netto CA, Wyse AT. Methylphenidate affects memory, brain-derived neurotrophic factor immunocontent and brain acetylcholinesterase activity in the rat. Neurobiol. Learn. Mem. 2010; 94: 247-53.
50. Shi X-Y, Wang J-W, Cui H, Li B-M, Lei G-F, Sun R-P. Effects of antiepileptic drugs on mRNA levels of BDNF and NT-3 and cell neogenesis in the developing rat brain. Brain Dev. 2010; 32: 229-35.
51. Halpin LE, Collins SA, Yamamoto BK. Neurotoxicity of methamphetamine and 3, 4-methylenedioxymethamphetamine. Life Sci. 2014; 97: 37-44.
52. Motaghinejad M, Motevalian M, Ebrahimzadeh A. Reduction of methylphenidate induced anxiety, depression and cognition impairment by various doses of venlafaxine in rat. Int. J. Prev. Med. 2015; 4: 52-60.
53. Motaghinejad M, Motevalian M, Larijani SF, Khajehamedi Z. Protective effects of forced exercise against methylphenidate-induced anxiety, depression and cognition impairment in rat. Adv. Biomed. Res. 2015; 27: 134-40.
54. Motaghinejad M, Karimian M, Motaghinejad O, Shabab B, Yazdani I, Fatima S. Protective effects of various dosage of Curcumin against morphine induced apoptosis and oxidative stress in rat isolated hippocampus. Pharmacol. Rep. 2015; 67: 230-5.
55. Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem. Func. 2002; 20: 171-5.
56. Dastgheib M, Dehpour A, Heidari M, Moezi L. The effects of intra-dorsal hippocampus infusion of pregnenolone sulfate on memory function and hippocampal BDNF mRNA expression of biliary cirrhosis-induced memory impairment in rats. Neuroscience 2015; 306: 1-9.
57. Banerjee R, Ghosh AK, Ghosh B, Bhattacharyya S, Mondal AC. Decreased mRNA and protein expression of BDNF, NGF, and their receptors in the hippocampus from suicide: an analysis in human postmortem brain. Clin. Med. Insights Pathol. 2013; 26: 1-11.
58. Hosseinzadeh S, Zahmatkesh M, Heidari M et al. Hippocampal DHCR24 down regulation in a rat model of streptozotocin-induced cognitive decline. Neurosci. Lett. 2015; 587: 107-12.